Skip to main content

Biomedical Research in Gynecology

This year, Dr. Eva Colas was nominated as co-director of the research group together with the former director Dr. Antonio Gil. This step proves the excellent reciprocal connection between translational and clinical research in the group. We have strength our translational research on endometrial and ovarian cancers and endometriosis. We signed 2 new agreements with biotechs and pharma, and obtained CPP, DTS and PI competitive projects. As well, we have strength our clinical research lines. We conducted several multicenter national studies through the research network of the Spanish Society of Gynecology and Obstetrics (Spain GOG, SEGO), and international clinical studies: RACC study, CERVANTES study, SENTICOL III, and PAROLA study, all in cervical cancer. Importantly, the clinical team become an Accredited Center for the training of fellows in Gynecological Oncology (ESGO) and in Breast Pathology (BRESO), and for the treatment of advanced ovarian cancer (ESGO).

eCORE

  • Cancer

Team

Group Leader
Antonio Gil Moreno, Eva Colàs

Principal Investigator (PI)
Antonio Gil Moreno, Eva Colás Ortega, Silvia Cabrera Díaz, Melissa Bradbury

Researchers
Cristian Moiola, Carlos López, Javier de la Torre, Martín Espinosa, Assumpció Pérez Benavente, Cristina Centeno, Martina Angeles Fité, Vicente Bebia, Anna Luzarraga, Laura Mañalich, Elena Suárez, Montse Cubo, Sonia Monreal, Diana Guerrero, Ursula Acosta, Josep Castellvi, Angel García, Carme Dinarés, Anna Ruano, Sabina Salicrú, Christian Sisó

PhD Students
Carina Masferrer, Beatriz Villafranca, Melek Denizli, Irene de la Calle, Raquel Delgado

Lab Technicians
Marta Rebull, Francesc Serra

Nursing and Technical Staff
Elisabeth Olivan

Publications

32
Publications
65.6
%Q1
246.30
Impact Factor
7.70
Average Impact Factor

Luzarraga Aznar A, Bebia V, López-Gil C, Giraldo A, Montoya MP, Verges R, Jauregui A, Castellvi J, Pérez-Benavente A, Colás E, Gil-Moreno A, Cabrera S
Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis.
Int J Gynecol Cancer. 2023 Oct 2;33(10):1564-1571
DOI: 10.1136/ijgc-2023-004534
IF: 4.8

Martinez-Garcia E, Coll-de la Rubia E, Lesur A, Dittmar G, Gil-Moreno A, Cabrera S, Colas E
Cervical Fluids Are a Source of Protein Biomarkers for Early, Non-Invasive Endometrial Cancer Diagnosis
Cancers (Basel). 2023 Jan 31;15(3):911
DOI: 10.3390/cancers15030911
IF: 5.2

Cabrera S, Gómez-Hidalgo NR, García-Pineda V, Bebia V, Fernández-González S, Alonso P, Rodríguez-Gómez T, Fusté P, Gracia-Segovia M, Lorenzo C, Chacon E, Roldan Rivas F, Arencibia O, Martí Edo M, Fidalgo S, Sanchis J, Padilla-Iserte P, Pantoja-Garrido M, Martínez S, Peiró R, Escayola C, Oliver-Pérez MR, Aghababyan C, Tauste C, Morales S, Torrent A, Utrilla-Layna J, Fargas F, Calvo A, Aller de Pace L, Gil-Moreno A; Spain-GOG and the MULTISENT Study Group
Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer
Ann Surg Oncol. 2023 Nov;30(12):7653-7662
DOI: 10.1245/s10434-023-14065-3
IF: 3.7

Casas-Arozamena C, Moiola CP, Vilar A, Bouso M, Cueva J, Cabrera S, Sampayo V, Arias E, Abalo A, García Á, Lago-Lestón RM, Oltra S, Díaz E, Ruiz-Bañobre J, López-López R, Moreno-Bueno G, Gil-Moreno A, Colás E, Abal M, Muinelo-Romay L.
Noninvasive detection of microsatellite instability in patients with endometrial cancer.
Int J Cancer. 2023 May 15;152(10):2206-2217
DOI: 10.1002/ijc.34435
IF: 7.3

Sengal AT, Bonazzi V, Smith D, Moiola CP, Lourie R, Rogers R, Colas E, Gil-Moreno A, Frentzas S, Chetty N, Perrin L, Pollock PM.
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition
NPJ Precis Oncol. 2023 Dec 8;7(1):127
DOI: 10.1038/s41698-023-00478-6.
IF: 7.9

Projects

Targeting the most aggressive type of endometrial carcinoma.
Principal Investigator: Antonio Gil Moreno
Agency: Asociacion Española Contra el Cancer
Funding: 1,000,000 €
Period: 2018-2024

ScreenEC: Development of a non-invasive IVD for endometrial cancer screening on high-risk populations
Principal Investigator: Antonio Gil / Eva Colás
Agency: Ministerio de Ciencia e Innovación
Funding: 1,506,847 € (VHIR 210,920 €)
Period: 2023-2026

WOMEC ADVANCED: Nuevas aproximaciones para el diagnóstico de cáncer de endometrio
Principal Investigator: Antonio Gil / Eva Colás
Agency: Ministerio de Ciencia e Innovación
Funding: 1,487,545.57 € (VHIR 369,335.50€)
Period: 2022 – 2024

Cytomark, desenvolupament d’un test de diagnòstic no invasiu de càncer d’endometri.
Principal Investigator: Eva Colás
Agency: AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA
Funding: 100,000 €
Period: 2022-2024

CytoMARK: Development of a personalised non-invasive diagnosis of endometrial cancer using proteomic markers in cervical fluids and clinical data
Principal Investigator: Eva Colás
Agency: ERA-Net Cofund. JTC 2021. European Comission; Instituto de Salud Carlos III; Asociación Española Contra el Cáncer.
Funding: 824,933 €
Period: 2022-2025

Patents

Biomarkers for endometrial cancer
Priority Number: EP21382680.3
Priority Date: 23/07/2021
Applicants: 80% VHIR; 20% LIH

Markers for endometrial cancer
Priority Number: PCT/EP2018/069841
Priority Date: 21/07/2017
Applicants: 100% VHIR

Markers of endometrial cancer
Priority Number: PCT/EP2017/057635
Priority Date: 04/05/2016
Applicants: 100% VHIR

VHIR Annual Report 2023